Pfizer going for it: Palbociclib NDA Q3 on Ph II
This article was originally published in Scrip
Executive Summary
Shares of Pfizer got a slight bump of 1.7% on 16 May after the company revealed it plans to jump ahead and seek the FDA's blessing in the third quarter to market palbociclib based on Phase II data.